Comunicazione EMA su Zinbryta (daclizumab) (07/07/2017)
L'Agenzia Europea dei Medicinali (EMA) limita l'uso del medicinale Zinbryta (daclizumab) per la sclerosi multipla.
Italiano
L'Agenzia Europea dei Medicinali (EMA) limita l'uso del medicinale Zinbryta (daclizumab) per la sclerosi multipla.
Il Comitato per la valutazione dei rischi per la farmacovigilanza (PRAC) dell’Agenzia Europea dei Medicinali (EMA) raccomanda che i medicinali iniettabili a base di metilprednisolone contenenti lattosio non devono essere somministrati ai pazienti allergici alle proteine del latte vaccino.
Using a device with a cracked/broken cartridge holder may result in the device delivering a reduced dose of insulin which could potentially lead to high blood sugar.
UPDATED 07/06/2017. Voluntary recall closed on June 23, 2017. FDA continues to recommend that health care providers discuss with their patients all available treatment options for CEA surgery.
Consumption of products containing derivatives of anabolic steroids may cause serious liver injury and other adverse health consequences, including kidney injury, increased risk of heart attack and stroke.
For pacing dependent patients, an interruption of pacing system could result in serious injury or death if not detected. Posted 07/06/2017
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti raccomandazioni in previsione della carenza della fornitura di CINRYZE.
Reasonable probability that the patient may experience adverse events ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis.
Reasonable probability that patient may experience adverse events ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis.
80.211.154.110